Canopus Biopharma Incorporated Stock Price Prediction
| CBIA Stock | USD 0.0001 0.00 0.00% |
Oversold Vs Overbought
46
Oversold | Overbought |
Using Canopus BioPharma hype-based prediction, you can estimate the value of Canopus BioPharma Incorporated from the perspective of Canopus BioPharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Canopus BioPharma to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Canopus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Canopus BioPharma after-hype prediction price | USD 8.7E-5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Canopus |
Canopus BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Canopus BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Canopus BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Canopus BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Canopus BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Canopus BioPharma's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Canopus BioPharma's historical news coverage. Canopus BioPharma's after-hype downside and upside margins for the prediction period are 0.00 and 40.29, respectively. We have considered Canopus BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Canopus BioPharma is out of control at this time. Analysis and calculation of next after-hype price of Canopus BioPharma is based on 3 months time horizon.
Canopus BioPharma Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Canopus BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Canopus BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Canopus BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
6.56 | 40.29 | 0.00 | 0.39 | 0 Events / Month | 2 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.0001 | 0.000087 | 13.23 |
|
Canopus BioPharma Hype Timeline
Canopus BioPharma is currently traded for 0.0001. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.39. Canopus is forecasted to decline in value after the next headline, with the price expected to drop to 8.7E-5. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -13.23%, whereas the daily expected return is currently at 6.56%. The volatility of related hype on Canopus BioPharma is about 67150.0%, with the expected price after the next announcement by competition of -0.39. The company had not issued any dividends in recent years. Canopus BioPharma had 1:15 split on the 16th of July 2007. Given the investment horizon of 90 days the next forecasted press release will be in 5 to 10 days. Check out Canopus BioPharma Basic Forecasting Models to cross-verify your projections.Canopus BioPharma Related Hype Analysis
Having access to credible news sources related to Canopus BioPharma's direct competition is more important than ever and may enhance your ability to predict Canopus BioPharma's future price movements. Getting to know how Canopus BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Canopus BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| INCC | International Consolidated Companies | 0.00 | 0 per month | 28.61 | 0.10 | 100.00 | (50.25) | 459.73 | |
| FRTG | Frontera Group | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| XCPL | XCPCNL Business Services | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ARMK | Aramark Holdings | (0.57) | 10 per month | 1.64 | 0 | 2.51 | (3.42) | 7.75 | |
| IJJP | Ijj Corporation | 0.00 | 0 per month | 10.21 | 0.07 | 33.33 | (25.00) | 86.67 | |
| DPUI | Discount Print USA | 0.00 | 0 per month | 17.20 | 0.11 | 100.00 | (33.33) | 150.00 | |
| SMX | SMX Public Limited | (0.04) | 9 per month | 14.82 | 0.01 | 59.09 | (25.00) | 162.33 | |
| SFRX | Seafarer Exploration | 0.00 | 0 per month | 0.00 | (0.12) | 8.33 | (9.09) | 23.85 | |
| OMEX | Odyssey Marine Exploration | 0.01 | 6 per month | 8.52 | 0.05 | 20.00 | (10.00) | 107.04 | |
| MMTRS | Mills Music Trust | 0.00 | 0 per month | 0.00 | (0.01) | 2.16 | (1.29) | 10.54 |
Canopus BioPharma Additional Predictive Modules
Most predictive techniques to examine Canopus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Canopus using various technical indicators. When you analyze Canopus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Canopus BioPharma Predictive Indicators
The successful prediction of Canopus BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Canopus BioPharma Incorporated, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Canopus BioPharma based on analysis of Canopus BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Canopus BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Canopus BioPharma's related companies.
Story Coverage note for Canopus BioPharma
The number of cover stories for Canopus BioPharma depends on current market conditions and Canopus BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Canopus BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Canopus BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Canopus BioPharma Short Properties
Canopus BioPharma's future price predictability will typically decrease when Canopus BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Canopus BioPharma Incorporated often depends not only on the future outlook of the potential Canopus BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Canopus BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Short Long Term Debt | 1.9 M |
Complementary Tools for Canopus Pink Sheet analysis
When running Canopus BioPharma's price analysis, check to measure Canopus BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canopus BioPharma is operating at the current time. Most of Canopus BioPharma's value examination focuses on studying past and present price action to predict the probability of Canopus BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canopus BioPharma's price. Additionally, you may evaluate how the addition of Canopus BioPharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |